Last reviewed · How we verify
Interferon Beta 1
Interferon Beta-1 activates interferon signaling pathways to enhance immune responses and reduce inflammatory cytokine production.
Interferon Beta-1 activates interferon signaling pathways to enhance immune responses and reduce inflammatory cytokine production. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.
At a glance
| Generic name | Interferon Beta 1 |
|---|---|
| Sponsor | University of Turin, Italy |
| Drug class | Type I interferon |
| Target | Interferon-alpha/beta receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Interferon Beta-1 is a type I interferon that binds to interferon-alpha/beta receptors on cell surfaces, triggering JAK-STAT signaling and upregulating antiviral and immunomodulatory genes. It enhances natural killer cell activity, increases expression of MHC molecules, and reduces pro-inflammatory cytokine production. In multiple sclerosis, it reduces the frequency and severity of relapses by modulating immune cell trafficking and reducing CNS inflammation.
Approved indications
- Relapsing-remitting multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
- Flu-like symptoms (fever, chills, myalgia)
- Injection site reactions
- Headache
- Fatigue
- Elevated liver enzymes
- Leukopenia
- Depression
Key clinical trials
- A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies (PHASE3)
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (PHASE1)
- An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (PHASE1)
- A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (PHASE1)
- Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma (PHASE1)
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |